{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:43:45Z","timestamp":1792421025480,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pembrolizumab, an immune checkpoint inhibitor (ICI), is an IgG4 antibody that blocks interaction between programmed cell death protein 1 and programmed death-ligand 1. Myocarditis, an immune-related adverse event, has been reported in thymic epithelial tumours. Pembrolizumab has also been associated with development\/exacerbation of myasthenia gravis (MG).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 70-year-old woman with metastatic thymic cancer presented to the hospital with shortness of breath, 21\u2009days after initiation of pembrolizumab. She was diagnosed with ICI-related myocarditis and was subsequently intubated due to respiratory failure. A dual-chamber pacemaker was placed due to complete heart block with asystole. Her troponin levels were elevated, an electrocardiogram was suspicious for myocardial infarction, but coronary angiogram revealed normal coronary arteries and endomyocardial biopsy confirmed the presence of myocarditis. Treatment was started with high-dose intravenous methylprednisolone and cardiovascular status improved. However, the patient was unable to be weaned from mechanical ventilation and tested positive for acetylcholine receptor binding\/blocking antibodies due to de novo MG. After 50\u2009days of hospitalization, she was discharged home in stable condition. A computed tomography scan was performed 6\u2009weeks after pembrolizumab; results showed significant decrease\/resolution of all measurable sites of metastatic disease in the lungs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This is the first reported case of a patient developing single-agent pembrolizumab-induced myocarditis concomitant with new-onset MG after treatment for advanced thymic malignancy. Additional studies are needed to explore the association between myocarditis, MG, and ICI therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaa051","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T07:15:20Z","timestamp":1586243720000},"page":"1-8","source":"Crossref","is-referenced-by-count":29,"title":["Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent\/metastatic thymic carcinoma patient: a case report"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-0569","authenticated-orcid":false,"given":"Charles","family":"Szuchan","sequence":"first","affiliation":[{"name":"Maroone Cancer Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9169-3321","authenticated-orcid":false,"given":"Leah","family":"Elson","sequence":"first","affiliation":[{"name":"Maroone Cancer Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Alley","sequence":"first","affiliation":[{"name":"Maroone Cancer Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-9105","authenticated-orcid":false,"given":"Kevin","family":"Leung","sequence":"first","affiliation":[{"name":"Heart and Vascular Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5072-6892","authenticated-orcid":false,"given":"Antonio Lewis","family":"Camargo","sequence":"first","affiliation":[{"name":"Heart and Vascular Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Elimimian","sequence":"first","affiliation":[{"name":"Maroone Cancer Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina","family":"Nahleh","sequence":"first","affiliation":[{"name":"Maroone Cancer Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Sadler","sequence":"first","affiliation":[{"name":"Heart and Vascular Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"2020062620240094900_ytaa051-B1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"2020062620240094900_ytaa051-B2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"2020062620240094900_ytaa051-B3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2017.02.001","article-title":"Novel immune check point inhibiting antibodies in cancer therapy\u2014opportunities and challenges","volume":"30","author":"Diesendruck","year":"2017","journal-title":"Drug Resist Updates"},{"key":"2020062620240094900_ytaa051-B4","volume-title":"KEYTRUDA (pembrolizumab) [package insert]","year":"2014"},{"key":"2020062620240094900_ytaa051-B5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"2020062620240094900_ytaa051-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcvm.2019.00003","article-title":"Cardiac complications in immune checkpoint inhibition therapy","volume":"6","author":"Tajiri","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"2020062620240094900_ytaa051-B7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020062620240094900_ytaa051-B8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"2020062620240094900_ytaa051-B9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","article-title":"Update on myocarditis","volume":"59","author":"Kindermann","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2020062620240094900_ytaa051-B10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"2020062620240094900_ytaa051-B11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2020062620240094900_ytaa051-B12","article-title":"Emerging concerns in cardio-oncology: immune checkpoint inhibitor cardiotoxicity","author":"Balanescu","journal-title":"American College of Cardiology. 24 June 2019; cited December 2019"},{"key":"2020062620240094900_ytaa051-B13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","article-title":"Immune checkpoint inhibitors and cardiac toxicity: an emerging issue","volume":"25","author":"Varricchi","year":"2018","journal-title":"Curr Med Chem"},{"key":"2020062620240094900_ytaa051-B14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2020062620240094900_ytaa051-B15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"2020062620240094900_ytaa051-B16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/cmi.2010.74","article-title":"Thymoma and autoimmunity","volume":"8","author":"Shelly","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"2020062620240094900_ytaa051-B17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-induced myocarditis concomitant with myasthenia gravis","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep Oncol"},{"key":"2020062620240094900_ytaa051-B18","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/j.jtho.2016.11.333","article-title":"OA18. 03 safety and clinical activity of Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced thymic epithelial tumors (TETs)","volume":"12","author":"Rajan","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2020062620240094900_ytaa051-B19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archneurol.2009.231","article-title":"Herzmyasthenie: myasthenia of the heart","volume":"66","author":"Aarli","year":"2009","journal-title":"Arch Neurol"},{"key":"2020062620240094900_ytaa051-B20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"2020062620240094900_ytaa051-B21","first-page":"9","article-title":"Treating with checkpoint inhibitors-figure $1 million per patient","volume":"8","author":"Andrews","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2020062620240094900_ytaa051-B22","year":"2018"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/4\/3\/1\/33434571\/ytaa051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/4\/3\/1\/33434571\/ytaa051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T08:02:26Z","timestamp":1593244946000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/4\/3\/1\/5816799"}},"subtitle":[],"editor":[{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Marco De","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Ciro","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Mark Philip","family":"Cassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Vishal Shahil","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaa051","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,4,7]]}}}